Characteristics, outcome, and prognostic factors of young patients with central nervous system World Health Organization grade 3 oligodendrogliomas IDH-mutant and 1p/19q codeleted: A French POLA network study

IF 5.1 2区 医学 Q1 ONCOLOGY Cancer Pub Date : 2025-03-30 DOI:10.1002/cncr.35814
Alexandre Bertucci MD, Ondine Dufour MD, Romain Appay MD, PhD, Vincent Harlay MD, François Ducray MD, PhD, Charlotte Bronnimann MD, Apolline Djelad MD, Elisabeth Cohen-Jonathan Moyal MD, PhD, Mario Campone MD, Olivier Langlois MD, Mathilde Ducloie MD, Elodie Vauleon MD, Nadia Younan MD, Christine Desenclos MD, Carole Ramirez MD, Mehdi Touat MD, PhD, Ahmed Idbaih MD, Céline Bequet, Dominique Figarella-Branger MD, PhD, Caroline Dehais MD, Olivier Chinot MD, Emeline Tabouret MD, PhD, for the POLA network
{"title":"Characteristics, outcome, and prognostic factors of young patients with central nervous system World Health Organization grade 3 oligodendrogliomas IDH-mutant and 1p/19q codeleted: A French POLA network study","authors":"Alexandre Bertucci MD,&nbsp;Ondine Dufour MD,&nbsp;Romain Appay MD, PhD,&nbsp;Vincent Harlay MD,&nbsp;François Ducray MD, PhD,&nbsp;Charlotte Bronnimann MD,&nbsp;Apolline Djelad MD,&nbsp;Elisabeth Cohen-Jonathan Moyal MD, PhD,&nbsp;Mario Campone MD,&nbsp;Olivier Langlois MD,&nbsp;Mathilde Ducloie MD,&nbsp;Elodie Vauleon MD,&nbsp;Nadia Younan MD,&nbsp;Christine Desenclos MD,&nbsp;Carole Ramirez MD,&nbsp;Mehdi Touat MD, PhD,&nbsp;Ahmed Idbaih MD,&nbsp;Céline Bequet,&nbsp;Dominique Figarella-Branger MD, PhD,&nbsp;Caroline Dehais MD,&nbsp;Olivier Chinot MD,&nbsp;Emeline Tabouret MD, PhD,&nbsp;for the POLA network","doi":"10.1002/cncr.35814","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Brain tumors represent one of the main causes of cancer-related mortality in young patients. Among them, oligodendrogliomas (OG) are adult-type diffuse gliomas with the best prognosis. Nevertheless, characterization of these tumors in the young population remains poorly documented. Our objective was to characterize the population of young adults under 40 years of age with grade 3 OG in the POLA cohort.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Clinical data prospectively collected for all patients registered with grade 3 OG between April 2009 and August 2021 were extracted from the national POLA database. This study compared the patient subgroup &lt;40 years of age to the one &gt;40 years of age.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The authors included 111 patients &lt;40 years old and 363 patients ≥40 years old. Treatment received did not differ significantly between the two subgroups. Temporal location was more frequent in older patients (<i>p</i> = .009). Patients &lt;40 years old presented more often seizure as initial symptom (<i>p</i> = .003). They had less frequent chromosome 9p loss (<i>p</i> &lt; .001) and less <i>CDKN2A</i> homozygous deletion (<i>p</i> = .024). Median progression-free survival (PFS) was 123 months (range, 86–not reached [NR]) versus 88 months (range, 67–117) (<i>p</i> = .082) and median overall survival (OS) was not reached (range, 147–NR) versus 163 months (range, 137–NR) (<i>p</i> &lt; .001) in younger and older subgroups, respectively. In multivariate analysis, complete or subtotal resection (<i>p</i> = .014) and seizure at diagnosis (<i>p</i> = .032) were associated with better OS.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Young patients with grade 3 OG have distinct clinical presentation, molecular features, and outcomes compared to the older patients.</p>\n </section>\n </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 7","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35814","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer","FirstCategoryId":"3","ListUrlMain":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35814","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Brain tumors represent one of the main causes of cancer-related mortality in young patients. Among them, oligodendrogliomas (OG) are adult-type diffuse gliomas with the best prognosis. Nevertheless, characterization of these tumors in the young population remains poorly documented. Our objective was to characterize the population of young adults under 40 years of age with grade 3 OG in the POLA cohort.

Methods

Clinical data prospectively collected for all patients registered with grade 3 OG between April 2009 and August 2021 were extracted from the national POLA database. This study compared the patient subgroup <40 years of age to the one >40 years of age.

Results

The authors included 111 patients <40 years old and 363 patients ≥40 years old. Treatment received did not differ significantly between the two subgroups. Temporal location was more frequent in older patients (p = .009). Patients <40 years old presented more often seizure as initial symptom (p = .003). They had less frequent chromosome 9p loss (p < .001) and less CDKN2A homozygous deletion (p = .024). Median progression-free survival (PFS) was 123 months (range, 86–not reached [NR]) versus 88 months (range, 67–117) (p = .082) and median overall survival (OS) was not reached (range, 147–NR) versus 163 months (range, 137–NR) (p < .001) in younger and older subgroups, respectively. In multivariate analysis, complete or subtotal resection (p = .014) and seizure at diagnosis (p = .032) were associated with better OS.

Conclusion

Young patients with grade 3 OG have distinct clinical presentation, molecular features, and outcomes compared to the older patients.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
世界卫生组织3级少突胶质细胞瘤idh突变和1p/19q编码的年轻中枢神经系统患者的特征、结局和预后因素:法国POLA网络研究
脑肿瘤是年轻患者癌症相关死亡的主要原因之一。其中,少突胶质细胞瘤(OG)是成人型弥漫性胶质瘤,预后最好。然而,这些肿瘤在年轻人群中的特征仍然缺乏文献记录。我们的目的是描述POLA队列中年龄在40岁以下的3级OG年轻人的特征。方法前瞻性收集2009年4月至2021年8月期间注册的所有3级OG患者的临床数据,提取自国家POLA数据库。本研究将40岁患者亚组与40岁患者亚组进行了比较。结果纳入年龄≥40岁的111例,年龄≥40岁的363例。接受的治疗在两个亚组之间没有显著差异。颞部定位在老年患者中更为常见(p = 0.009)。40岁患者以癫痫发作为首发症状较多(p = 0.003)。染色体9p丢失的频率较低(p <;.001)和较少的CDKN2A纯合缺失(p = .024)。中位无进展生存期(PFS)为123个月(范围,86 -未达到[NR])与88个月(范围,67-117)(p = 0.082),中位总生存期(OS)未达到(范围,147-NR)与163个月(范围,137-NR) (p <;.001)。在多变量分析中,完全或次全切除(p = 0.014)和诊断时癫痫发作(p = 0.032)与更好的OS相关。结论与老年患者相比,年轻3级OG患者具有明显的临床表现、分子特征和预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer
Cancer 医学-肿瘤学
CiteScore
13.10
自引率
3.20%
发文量
480
审稿时长
2-3 weeks
期刊介绍: The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society. CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines: blood/bone marrow; breast disease; endocrine disorders; epidemiology; gastrointestinal tract; genitourinary disease; gynecologic oncology; head and neck disease; hepatobiliary tract; integrated medicine; lung disease; medical oncology; neuro-oncology; pathology radiation oncology; translational research
期刊最新文献
The myeloma divide: How sex and age shape disease characteristics. Combination of mitoxantrone hydrochloride liposome with cyclophosphamide, vincristine, and prednisone for patients with treatment-naive peripheral T-cell lymphoma: A multicenter, open-label, single-arm, phase 1b trial. Psychosocial factors and the risk of cancer: An individual-participant data meta-analysis. The impact of the patient macroenvironment on molecular subgroups in endometrial cancer. Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1